These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 7647222)

  • 1. Tissue factor pathway inhibitor: proposed heparin recognition region.
    Harenberg J; Malsch R; Heene DL
    Blood Coagul Fibrinolysis; 1995 Jun; 6 Suppl 1():S50-6. PubMed ID: 7647222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The present status of tissue factor pathway inhibitor.
    Lindahl AK; Sandset PM; Abildgaard U
    Blood Coagul Fibrinolysis; 1992 Aug; 3(4):439-49. PubMed ID: 1420819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix localization of tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor (TFPI-2/MSPI) involves arginine-mediated ionic interactions with heparin and dermatan sulfate: heparin accelerates the activity of TFPI-2/MSPI toward plasmin.
    Liu Y; Stack SM; Lakka SS; Khan AJ; Woodley DT; Rao JS; Rao CN
    Arch Biochem Biophys; 1999 Oct; 370(1):112-8. PubMed ID: 10496984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins.
    Valentin S; Nordfang O; Bregengård C; Wildgoose P
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):713-20. PubMed ID: 8292720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of lipoprotein lipase activity by tissue factor pathway inhibitor.
    Mukherjee M; Kakkar VV
    Thromb Haemost; 1999 Dec; 82(6):1648-51. PubMed ID: 10613650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparins.
    Harenberg J; Siegele M; Dempfle CE; Stehle G; Heene DL
    Thromb Haemost; 1993 Dec; 70(6):942-5. PubMed ID: 8165616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue factor pathway inhibitor; its structure, function and clinical significance.
    Kato H
    Pol J Pharmacol; 1996; 48(1):67-72. PubMed ID: 9112630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure and biology of tissue factor pathway inhibitor.
    Bajaj MS; Birktoft JJ; Steer SA; Bajaj SP
    Thromb Haemost; 2001 Oct; 86(4):959-72. PubMed ID: 11686353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8.
    Cunningham AC; Hasty KA; Enghild JJ; Mast AE
    Biochem J; 2002 Oct; 367(Pt 2):451-8. PubMed ID: 12117418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins.
    Alban S; Gastpar R
    Thromb Haemost; 2001 May; 85(5):824-9. PubMed ID: 11372675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravascular release and urinary excretion of tissue factor pathway inhibitor during heparin treatment.
    Brodin E; Svensson B; Paulssen RH; Nordoy A; Hansen JB
    J Lab Clin Med; 2004 Nov; 144(5):246-53; discussion 226-7. PubMed ID: 15570242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular weight-dependent influence of heparin on the form of tissue factor pathway inhibitor circulating in plasma.
    Alban S
    Semin Thromb Hemost; 2001 Oct; 27(5):503-11. PubMed ID: 11668420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity of plasma tissue factor pathway inhibitor.
    Broze GJ; Lange GW; Duffin KL; MacPhail L
    Blood Coagul Fibrinolysis; 1994 Aug; 5(4):551-9. PubMed ID: 7841311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycosaminoglycan specificity of a heparin-binding peptide.
    Taylor GJ; Yorke SC; Harding DR
    Pept Res; 1995; 8(5):286-93. PubMed ID: 8589551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of full length and two-domain tissue factor pathway inhibitor in combination with heparin in rabbits.
    Bregengaard C; Nordfang O; Ostergaard P; Petersen JG; Meyn G; Diness V; Svendsen O; Hedner U
    Thromb Haemost; 1993 Sep; 70(3):454-7. PubMed ID: 8259548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin.
    Wesselschmidt R; Likert K; Huang Z; MacPhail L; Broze GJ
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):661-9. PubMed ID: 8292716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The second Kunitz domain of human tissue factor pathway inhibitor: cloning, structure determination and interaction with factor Xa.
    Burgering MJ; Orbons LP; van der Doelen A; Mulders J; Theunissen HJ; Grootenhuis PD; Bode W; Huber R; Stubbs MT
    J Mol Biol; 1997 Jun; 269(3):395-407. PubMed ID: 9199408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of depolymerized holothurian glycosaminoglycan (DHG) on tissue factor pathway inhibitor: in vitro and in vivo studies.
    Nagase H; Enjyoji K; Kamikubo Y; Kitazato KT; Kitazato K; Saito H; Kato H
    Thromb Haemost; 1997 Aug; 78(2):864-70. PubMed ID: 9268186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man.
    Holst J; Lindblad B; Bergqvist D; Hedner U; Nordfang O; Ostergaard P
    Thromb Res; 1997 May; 86(4):343-8. PubMed ID: 9187023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans.
    Valentin S; Larnkjer A; Ostergaard P; Nielsen JI; Nordfang O
    Thromb Res; 1994 Jul; 75(2):173-83. PubMed ID: 7974391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.